Sangeet Ghai1, Alyssa S Louis2, Meghan Van Vliet1, Uri Lindner2, Masoom A Haider1, Eugen Hlasny1, Paula Spensieri1, Theodorus H Van Der Kwast3, Stuart A McCluskey4, Walter Kucharczyk1, John Trachtenberg2. 1. 1 Department of Medical Imaging, University Health Network, Mount Sinai Hospital, Women's College Hospital, University of Toronto, Toronto General Hospital, 585 University Ave, Toronto ON M5G 2N2, Canada. 2. 2 Department of Surgical Oncology, Division of Urology, University Health Network, University of Toronto, Toronto ON, Canada. 3. 3 Department of Pathology and Laboratory Medicine, University Health Network, University of Toronto, Toronto ON, Canada. 4. 4 Department of Anesthesia and Pain Management, University Health Network, University of Toronto, Toronto, ON, Canada.
Abstract
OBJECTIVE: Focal therapy is an emerging approach to the treatment of localized prostate cancer. The purpose of this study was to report the 6-month follow-up oncologic and functional data of the initial phase 1 trial of patients treated with focal transrectal MRI-guided focused ultrasound in North America. SUBJECTS AND METHODS: Four patients with a prostate-specific antigen (PSA) level of 10 ng/mL or less, tumor classification cT2a or less, and a Gleason score of 6 (3 + 3) were prospectively enrolled in the study and underwent multiparametric MRI and transrectal ultrasound-guided prostate systematic biopsy. Under MRI guidance and real-time monitoring with MR thermography, focused high-frequency ultrasound energy was delivered to ablate the target tissue. The incidence and severity of treatment-related adverse events were recorded along with responses to serial quality-of-life questionnaires for 6 months after treatment. Oncologic outcomes were evaluated with multiparametric MRI and repeat transrectal ultrasound-guided biopsy 6 months after treatment. RESULTS: Four patients with a total of six target lesions were treated and had complications graded Clavien-Dindo I or less. Quality-of-life parameters were similar between baseline and 6-months. All four patients had normal MRI findings in the treated regions (100%), biopsy showed that three patients (75%) were clear of disease in the treated regions, representing complete ablation of five target lesions (83%). All patients had at least one Gleason 6-positive core outside of the treated zone. CONCLUSION: MRI-guided focused ultrasound is a feasible method of noninvasively ablating low-risk prostate cancers with low morbidity. Further investigation and follow-up are warranted in a larger patient series with appropriate statistical analysis of oncologic and functional outcome measures.
OBJECTIVE: Focal therapy is an emerging approach to the treatment of localized prostate cancer. The purpose of this study was to report the 6-month follow-up oncologic and functional data of the initial phase 1 trial of patients treated with focal transrectal MRI-guided focused ultrasound in North America. SUBJECTS AND METHODS: Four patients with a prostate-specific antigen (PSA) level of 10 ng/mL or less, tumor classification cT2a or less, and a Gleason score of 6 (3 + 3) were prospectively enrolled in the study and underwent multiparametric MRI and transrectal ultrasound-guided prostate systematic biopsy. Under MRI guidance and real-time monitoring with MR thermography, focused high-frequency ultrasound energy was delivered to ablate the target tissue. The incidence and severity of treatment-related adverse events were recorded along with responses to serial quality-of-life questionnaires for 6 months after treatment. Oncologic outcomes were evaluated with multiparametric MRI and repeat transrectal ultrasound-guided biopsy 6 months after treatment. RESULTS: Four patients with a total of six target lesions were treated and had complications graded Clavien-Dindo I or less. Quality-of-life parameters were similar between baseline and 6-months. All four patients had normal MRI findings in the treated regions (100%), biopsy showed that three patients (75%) were clear of disease in the treated regions, representing complete ablation of five target lesions (83%). All patients had at least one Gleason 6-positive core outside of the treated zone. CONCLUSION: MRI-guided focused ultrasound is a feasible method of noninvasively ablating low-risk prostate cancers with low morbidity. Further investigation and follow-up are warranted in a larger patient series with appropriate statistical analysis of oncologic and functional outcome measures.
Entities:
Keywords:
MRI-guided high-intensity focused ultrasound; focal therapy; prostate cancer
Authors: David Bonekamp; M B Wolf; M C Roethke; S Pahernik; B A Hadaschik; G Hatiboglu; T H Kuru; I V Popeneciu; J L Chin; M Billia; J Relle; J Hafron; K R Nandalur; R M Staruch; M Burtnyk; M Hohenfellner; H-P Schlemmer Journal: Eur Radiol Date: 2018-06-25 Impact factor: 5.315
Authors: D Hausmann; N Aksöz; J von Hardenberg; T Martini; N Westhoff; S Buettner; S O Schoenberg; P Riffel Journal: Eur Radiol Date: 2017-08-10 Impact factor: 5.315
Authors: Elena A Kaye; Sebastien Monette; Govindarajan Srimathveeravalli; Majid Maybody; Stephen B Solomon; Amitabh Gulati Journal: Int J Hyperthermia Date: 2016-07-21 Impact factor: 3.914
Authors: Arvin K George; Baris Turkbey; Subin G Valayil; Akhil Muthigi; Francesca Mertan; Michael Kongnyuy; Peter A Pinto Journal: Abdom Radiol (NY) Date: 2016-05
Authors: Sangeet Ghai; Nathan Perlis; Uri Lindner; Eugen Hlasny; Masoom A Haider; Antonio Finelli; Alexandre R Zlotta; Girish S Kulkarni; Theodorus H van der Kwast; Stuart A McCluskey; Walter Kucharczyk; John Trachtenberg Journal: Eur Radiol Date: 2018-04-25 Impact factor: 5.315